• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer.

作者信息

Tseng Diane, Padda Sukhmani K, Wakelee Heather A

机构信息

Stanford Cancer Institute, Stanford University, Stanford, California.

Stanford Cancer Institute, Stanford University, Stanford, California.

出版信息

J Thorac Oncol. 2018 Jun;13(6):741-744. doi: 10.1016/j.jtho.2018.04.008.

DOI:10.1016/j.jtho.2018.04.008
PMID:29793645
Abstract
摘要

相似文献

1
Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer.非小细胞肺癌患者对PD-1轴抑制剂获得性耐药的研究视角
J Thorac Oncol. 2018 Jun;13(6):741-744. doi: 10.1016/j.jtho.2018.04.008.
2
Subsequent strategies and underlying mechanism of acquired resistance to PD-1 axis inhibitors in advanced non-small cell lung cancer.晚期非小细胞肺癌中对PD-1轴抑制剂获得性耐药的后续策略及潜在机制。
Chin Med J (Engl). 2024 Apr 5;137(7):880-882. doi: 10.1097/CM9.0000000000003015. Epub 2024 Mar 15.
3
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.非小细胞肺癌患者在接受PD-1/PD-L1抑制剂治疗后接受挽救性化疗的反应率增加。
J Thorac Oncol. 2018 Apr;13(4):e55-e56. doi: 10.1016/j.jtho.2017.11.113.
4
Response to Costantini et al. "Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer".对科斯坦蒂尼等人《关于非小细胞肺癌患者在使用PD-1/PD-L1抑制剂后进行挽救性化疗时反应率增加的评论》的回应
J Thorac Oncol. 2018 Apr;13(4):e56-e57. doi: 10.1016/j.jtho.2017.11.122.
5
Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer.将程序性死亡-1抑制剂应用于非小细胞肺癌的一线治疗
J Clin Oncol. 2016 Sep 1;34(25):2953-5. doi: 10.1200/JCO.2016.68.1205. Epub 2016 Jul 5.
6
Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.程序性细胞死亡蛋白1配体1异质性在非小细胞肺癌患者接受免疫治疗选择中的意义
Clin Pharmacol Ther. 2016 Sep;100(3):220-2. doi: 10.1002/cpt.360. Epub 2016 May 3.
7
Are We Ready to Safely Combine Anti-PD-1/PD-L1 with Cranial Irradiation in Non-Small Cell Lung Cancer Patients?我们是否准备好安全地将抗PD-1/PD-L1与头部放疗联合用于非小细胞肺癌患者？
J Thorac Oncol. 2018 Apr;13(4):475-477. doi: 10.1016/j.jtho.2018.02.019.
8
Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?免疫检查点抑制剂在非小细胞肺癌中的联合策略：我们处于什么位置？
Clin Lung Cancer. 2018 Jan;19(1):1-11. doi: 10.1016/j.cllc.2017.06.005. Epub 2017 Jun 23.
9
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.PD-L1 表达在非小细胞肺癌中的意义：作为预测和预后标志物的锐利双刃剑。
Clin Lung Cancer. 2018 Mar;19(2):120-129. doi: 10.1016/j.cllc.2017.10.014. Epub 2017 Oct 28.
10
Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.PD-1/PD-L1 抑制剂在未经治疗和化疗耐药的非小细胞肺癌患者中的安全性和疗效：系统评价和荟萃分析。
Clin Lung Cancer. 2018 May;19(3):e335-e348. doi: 10.1016/j.cllc.2018.01.002. Epub 2018 Jan 10.

引用本文的文献

1
Clinical study of adebrelimab in combination with apatinib and irinotecan for PD-1 inhibitor-ineffective advanced-stage gastric cancer: study protocol for a single-arm, single-centre, exploratory trial.阿得贝利单抗联合阿帕替尼和伊立替康治疗PD-1抑制剂无效的晚期胃癌的临床研究：一项单臂、单中心探索性试验的研究方案
BMJ Open. 2025 Jun 4;15(6):e089286. doi: 10.1136/bmjopen-2024-089286.
2
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.Src 家族激酶（SFK）抑制剂达沙替尼通过抑制调节性 T 细胞（Treg）的转化和增殖，提高抗 PD-1 在 NSCLC 模型中的抗肿瘤活性。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001496.
3
MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential.
非小细胞肺癌中的 microRNAs：基因调控、对癌症细胞过程的影响及治疗潜力。
Pharmacol Res Perspect. 2019 Dec;7(6):e00528. doi: 10.1002/prp2.528.
4
Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells.环状 RNA circFGFR1 通过海绵吸附 miR-381-3p 促进非小细胞肺癌细胞的进展和抗 PD-1 耐药性。
Mol Cancer. 2019 Dec 9;18(1):179. doi: 10.1186/s12943-019-1111-2.